| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |